A Detailed Clinical Case of Localized Prostate Tumors Treated with Nanoparticle-Assisted Sub-Ablative Laser Ablation

Simple item page
dc.citation.articleNumber1261en_US
dc.citation.issueNumber15en_US
dc.citation.journalTitleNanomaterialsen_US
dc.citation.volumeNumber14en_US
dc.contributor.authorKadria-Vili, Yaraen_US
dc.contributor.authorSchwartz, Jon A.en_US
dc.contributor.authorPolascik, Thomas J.en_US
dc.contributor.authorGoodrich, Glenn P.en_US
dc.contributor.authorJorden, Daviden_US
dc.contributor.authorPinder, Dianeen_US
dc.contributor.authorHalas, Naomi J.en_US
dc.contributor.authorRastinehad, Ardeshir R.en_US
dc.contributor.orgLaboratory for Nanophotonicsen_US
dc.date.accessioned2024-08-29T21:11:48Zen_US
dc.date.available2024-08-29T21:11:48Zen_US
dc.date.issued2024en_US
dc.description.abstractAuroLase® Therapy—a nanoparticle-enabled focal therapy—has the potential to safely and effectively treat localized prostate cancer (PCa), preserving baseline functionality. This article presents a detailed case of localized PCa treated with AuroLase, providing insight on expectations from the diagnosis of PCa to one year post-treatment. AuroLase Therapy is a two-day treatment consisting of a systemic infusion of gold nanoshells (~150-nm hydrodynamic diameter) on Day 1, and sub-ablative laser treatment on Day 2. Multiparametric MRI (mpMRI) was used for tumor visualization, treatment planning, and therapy response assessment. The PCa was targeted with a MR/Ultrasound-fusion (MR/US) transperineal approach. Successful treatment was confirmed at 6 and 12 months post-treatment by the absence of disease in MR/US targeted biopsies. On the mpMRI, confined void space was evident, an indication of necrotic tissues encompassing the treated lesion, which was completely resolved at 12 months, forming a band-like scar with no evidence of recurrent tumor. The patient’s urinary and sexual functions were unchanged. During the one-year follow-up, changes on the DCE sequence and in the Ktrans and ADC values assist in qualitatively and quantitatively evaluating tissue changes. The results highlight the potential of gold-nanoparticle-enabled sub-ablative laser treatment to target and control localized PCa, maintain quality of life, and preserve baseline functionality.en_US
dc.identifier.citationKadria-Vili, Y., Schwartz, J. A., Polascik, T. J., Goodrich, G. P., Jorden, D., Pinder, D., Halas, N. J., & Rastinehad, A. R. (2024). A Detailed Clinical Case of Localized Prostate Tumors Treated with Nanoparticle-Assisted Sub-Ablative Laser Ablation. Nanomaterials, 14(15), Article 15. https://doi.org/10.3390/nano14151261en_US
dc.identifier.digitalnanomaterials-14-01261-v2en_US
dc.identifier.doihttps://doi.org/10.3390/nano14151261en_US
dc.identifier.urihttps://hdl.handle.net/1911/117737en_US
dc.language.isoengen_US
dc.publisherMDPIen_US
dc.rightsExcept where otherwise noted, this work is licensed under a Creative Commons Attribution (CC BY) license.  Permission to reuse, publish, or reproduce the work beyond the terms of the license or beyond the bounds of fair use or other exemptions to copyright law must be obtained from the copyright holder.en_US
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/en_US
dc.titleA Detailed Clinical Case of Localized Prostate Tumors Treated with Nanoparticle-Assisted Sub-Ablative Laser Ablationen_US
dc.typeJournal articleen_US
dc.type.dcmiTexten_US
dc.type.publicationpublisher versionen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
nanomaterials-14-01261-v2.pdf
Size:
5.93 MB
Format:
Adobe Portable Document Format
Download
Collections
Faculty Publications
Chemistry Publications
ECE Publications
Physics and Astronomy Publications